Bullfrog AI Holdings, Inc. (BFRG)
| Market Cap | 10.89M -35.8% |
| Revenue (ttm) | 116,670 |
| Net Income | -6.07M |
| EPS | -0.54 |
| Shares Out | 18.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 314,204 |
| Open | 0.5910 |
| Previous Close | 0.5913 |
| Day's Range | 0.5725 - 0.6100 |
| 52-Week Range | 0.4251 - 2.0400 |
| Beta | -3.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About BFRG
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebend... [Read more]
Financial Performance
Financial StatementsNews
Bullfrog AI regains compliance with Nasdaq
BullFrog AI (BFRG) announced that it has received a written notice from Nasdaq stating that the company has regained compliance with the minimum stockholders’ equity requirement under Nasdaq Listing R...
BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and m...
BullFrog AI Announces Participation at AACR Annual Meeting
BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957 BullFrog AI team will be available to discuss its end-to-end drug discovery and devel...
BullFrog AI issues shareholder letter highlighting recent progress, outlook
BullFrog AI (BFRG) issued a letter to shareholders from founder and CEO Vin Singh stating the company has secured the financial runway to execute its strategy into late 2027 and…
BullFrog AI issues shareholder letter highlighting recent progress, outlook
BullFrog AI (BFRG) issued a letter to shareholders from founder and CEO Vin Singh stating the company has secured the financial runway to execute its strategy into late 2027 and…
BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners
GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and machine ...
Bullfrog AI stock offers a rare opportunity for investors to take profit
Bullfrog AI Inc more than doubled on Mar. 30 after announcing a landmark commercial agreement with a “top 5” pharma leader to identify novel therapeutic targets for Major Depressive Disorder. In its p...
Bullfrog AI enters commercial agreement with pharmaceutical company
BullFrog AI (BFRG) announced a commercial agreement with a global pharmaceutical company to apply the company’s proprietary bfLEAP platform to identify and prioritize novel drug targets in major depre...
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder
GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and m...
BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine
Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D...
BullFrog to Host Webinar on New Precision AI Capability
March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design March 27 webinar at 11 a.m. ET high...
Bullfrog AI to unveil new precision AI capability
BullFrog AI (BFRG) Holdings announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. Key capabilities include: Compares drug...
BullFrog AI to Unveil New Precision AI Capability
GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and ma...
Bullfrog AI publishes whitepaper on data harmonization
BullFrog AI (BFRG) Holdings publishes a white paper titled, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” with a discussion on how BullFrog AI’s bfPREP immediately...
Bullfrog AI highlights presentation of data from bfLEAP
BullFrog AI (BFRG) highlights the presentation of data derived from the use of the Company’s proprietary platform bfLEAP with pancreatic cancer trial data to identify an almost three times increase…
BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer
Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI Company's bfLEAP® pl...
Bullfrog AI sees several developments as ‘important catalysts’ in 2026
BullFrog AI (BFRG) Holdings announced the release of its annual letter to shareholders, which read in part, “As we close 2025, I want to thank you for your continued support…
Bullfrog AI publishes whitepaper on AI in Bioinformatics
BullFrog AI (BFRG) Holdings announced the publication of a new whitepaper titled “AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks. “The life sciences in...
Bullfrog AI files to sell 5M shares of common stock for holders
17:25 EDT Bullfrog AI (BFRG) files to sell 5M shares of common stock for holders
Bullfrog AI announces expansion of internal sales organization
BullFrog AI (BFRG) Holdings announced the expansion of its internal sales organization to support accelerated commercialization of the Company’s clinical trial optimization offerings, including its re...
Bullfrog AI, Sygnature announces official sales launch of BullFrog networks
BullFrog AI (BFRG) announced that its collaboration with Sygnature Discovery specializing in drug discovery, has entered the commercial phase. With the formal sales kickoff on September 12, BullFrog A...
Bullfrog AI to showcase AI-powered clinical data solutions in Xtalks Webinar
BullFrog AI (BFRG) Holdings announced that its Director of AI, Machine Learning & Innovation, Juan Felipe Beltran Lacouture, PhD, will present a live webinar hosted by Xtalks titled “Clinical Data…
Bullfrog AI provides update on collaboration with Eleison
BullFrog AI (BFRG) Holdings provided an update on its collaboration with Eleison Pharmaceuticals. To support this collaboration, BullFrog AI developed a new data ingestion module, purpose-built to han...
BullFrog AI's bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration
Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI's enterprise-grade platform strategy, combining automation and human-in-the-loop oversight...
BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial i...